How do hospital characteristics and ties relate to the uptake of second-generation biosimilars?

Detalhes bibliográficos
Autor(a) principal: Perelman, Julian
Data de Publicação: 2023
Outros Autores: Duarte-Ramos, Filipa, Melo Gouveia, António, Pinheiro, Luis, Ramos, Francisco, Vogler, Sabine, Mateus, Céu
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/151551
Resumo: Funding Information: This study was financed by an unrestricted grant by the Portuguese Association of Generics and Biosimilars (APOGEN) to the Nova National School of Public Health. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript. The funder was informed that the paper was submitted, and agreed with the submission. Authors not affiliated to the Nova National School of Public Health did not receive any funding for participating in this study. Publisher Copyright: © 2022 Informa UK Limited, trading as Taylor & Francis Group.
id RCAP_296249be21dbc5930ee0649986620a14
oai_identifier_str oai:run.unl.pt:10362/151551
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling How do hospital characteristics and ties relate to the uptake of second-generation biosimilars?a longitudinal analysis of Portuguese NHS hospitals, 2015–2021Biosimilardiffusionhospital-related determinantsintra-country differencesPortugalsavingsuptakeHealth PolicyPharmacology (medical)SDG 3 - Good Health and Well-beingFunding Information: This study was financed by an unrestricted grant by the Portuguese Association of Generics and Biosimilars (APOGEN) to the Nova National School of Public Health. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript. The funder was informed that the paper was submitted, and agreed with the submission. Authors not affiliated to the Nova National School of Public Health did not receive any funding for participating in this study. Publisher Copyright: © 2022 Informa UK Limited, trading as Taylor & Francis Group.Background: There is limited evidence on within-country discrepancies in biosimilar uptake. This study analyzes differences in timing and diffusion of biosimilar uptake across Portuguese NHS hospitals and explores possible determinants. Research design and methods: We analyzed publicly accessible consumption data of originator biologic and biosimilar drugs for adalimumab, etanercept, infliximab, rituximab, and trastuzumab, by hospital and month for the years 2015–2021 (N = 9,467). We modeled the time to biosimilar adoption using survival regression models and the share of biosimilar consumption using generalized estimated equations with random hospital effects. Results: Academic hospitals were characterized by a quicker uptake of adalimumab and infliximab biosimilars but lower shares for other drugs. A higher total consumption of biologics was related to a lower share of biosimilar uptake. A stronger participation in randomized controlled trials was linked to higher biosimilar shares and quicker uptake, except for rituximab. If all NHS hospitals had biosimilar shares equal to the highest ones, potential annual savings could reach 13.9 million euros. Conclusion: The findings suggest a need for capacity-building on biosimilar prescribing, including for doctors of academic hospitals and those working in settings where high biosimilar use would be expected.Escola Nacional de Saúde Pública (ENSP)Comprehensive Health Research Centre (CHRC) - Pólo ENSPCentro de Investigação em Saúde Pública (CISP/PHRC)RUNPerelman, JulianDuarte-Ramos, FilipaMelo Gouveia, AntónioPinheiro, LuisRamos, FranciscoVogler, SabineMateus, Céu2023-04-03T22:16:08Z20232023-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article11application/pdfhttp://hdl.handle.net/10362/151551eng1473-7167PURE: 57576453https://doi.org/10.1080/14737167.2023.2146579info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:33:59Zoai:run.unl.pt:10362/151551Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:54:37.986232Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv How do hospital characteristics and ties relate to the uptake of second-generation biosimilars?
a longitudinal analysis of Portuguese NHS hospitals, 2015–2021
title How do hospital characteristics and ties relate to the uptake of second-generation biosimilars?
spellingShingle How do hospital characteristics and ties relate to the uptake of second-generation biosimilars?
Perelman, Julian
Biosimilar
diffusion
hospital-related determinants
intra-country differences
Portugal
savings
uptake
Health Policy
Pharmacology (medical)
SDG 3 - Good Health and Well-being
title_short How do hospital characteristics and ties relate to the uptake of second-generation biosimilars?
title_full How do hospital characteristics and ties relate to the uptake of second-generation biosimilars?
title_fullStr How do hospital characteristics and ties relate to the uptake of second-generation biosimilars?
title_full_unstemmed How do hospital characteristics and ties relate to the uptake of second-generation biosimilars?
title_sort How do hospital characteristics and ties relate to the uptake of second-generation biosimilars?
author Perelman, Julian
author_facet Perelman, Julian
Duarte-Ramos, Filipa
Melo Gouveia, António
Pinheiro, Luis
Ramos, Francisco
Vogler, Sabine
Mateus, Céu
author_role author
author2 Duarte-Ramos, Filipa
Melo Gouveia, António
Pinheiro, Luis
Ramos, Francisco
Vogler, Sabine
Mateus, Céu
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Escola Nacional de Saúde Pública (ENSP)
Comprehensive Health Research Centre (CHRC) - Pólo ENSP
Centro de Investigação em Saúde Pública (CISP/PHRC)
RUN
dc.contributor.author.fl_str_mv Perelman, Julian
Duarte-Ramos, Filipa
Melo Gouveia, António
Pinheiro, Luis
Ramos, Francisco
Vogler, Sabine
Mateus, Céu
dc.subject.por.fl_str_mv Biosimilar
diffusion
hospital-related determinants
intra-country differences
Portugal
savings
uptake
Health Policy
Pharmacology (medical)
SDG 3 - Good Health and Well-being
topic Biosimilar
diffusion
hospital-related determinants
intra-country differences
Portugal
savings
uptake
Health Policy
Pharmacology (medical)
SDG 3 - Good Health and Well-being
description Funding Information: This study was financed by an unrestricted grant by the Portuguese Association of Generics and Biosimilars (APOGEN) to the Nova National School of Public Health. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript. The funder was informed that the paper was submitted, and agreed with the submission. Authors not affiliated to the Nova National School of Public Health did not receive any funding for participating in this study. Publisher Copyright: © 2022 Informa UK Limited, trading as Taylor & Francis Group.
publishDate 2023
dc.date.none.fl_str_mv 2023-04-03T22:16:08Z
2023
2023-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/151551
url http://hdl.handle.net/10362/151551
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1473-7167
PURE: 57576453
https://doi.org/10.1080/14737167.2023.2146579
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 11
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138134678568960

Registros relacionados